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Abstract 
Bioterrorism agents that can be easily transmitted with high mortality rates and cause debilitating 
diseases pose major threats to national security and public health. The recent Ebola virus 
outbreak in West Africa and ongoing Zika virus outbreak in Brazil, now spreading throughout 
Latin America, are case examples of emerging infectious pathogens that have incited widespread 
fear and economic and social disruption on a global scale. Prophylactic vaccines would provide 
effective countermeasures against infectious pathogens and biological warfare agents. However, 
traditional approaches relying on attenuated or inactivated vaccines have been hampered by their 
unacceptable levels of reactogenicity and safety issues, whereas subunit antigen-based vaccines 
suffer from suboptimal immunogenicity and efficacy. In contrast, particulate vaccine delivery 
systems offer key advantages, including efficient and stable delivery of subunit antigens, 
co-delivery of adjuvant molecules to bolster immune responses, low reactogenicity due to the use 
of biocompatible biomaterials, and robust efficiency to elicit humoral and cellular immunity in 
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systemic and mucosal tissues. Thus, vaccine nanoparticles and microparticles are promising 
platforms for clinical development of biodefense vaccines. In this review, we summarize the 
current status of research efforts to develop particulate vaccine delivery systems against 
bioterrorism agents and emerging infectious pathogens. 
Introduction 
The United States Centers for Disease Control and Prevention (CDC) has classified bioterrorism 
agents into three categories.1 Category A pathogens are associated with the highest risk to 
national security and public health due to their ease of dissemination and high mortality rates. 
Category B pathogens are of the second highest priority with moderate ease of dissemination and 
mortality rates while category C includes infectious pathogens that could be modified for 
widespread dissemination. Many of these emerging infectious pathogens are zoonotic without 
any available prophylactic vaccines or effective post-exposure treatments, and their natural 
outbreak or malicious dissemination can have grave consequences, as recently manifested during 
the outbreaks of Ebola virus in West Africa and Zika virus in Brazil that have caused widespread 
fear and economic and social disruption on a global scale. Therefore, there is an urgent need for 
vaccines that can elicit concerted cellular and humoral immune responses and establish 
protective immunity against pathogens with spared doses and short-term immunization regimens. 
In addition, it is critical to maintain robust public preparedness programs with sufficient vaccine 
stockpiles that can be distributed readily to protect the general public. Such organizational 
preparedness rooted in robust vaccine programs will also have the added benefits of deterring 
any terrorist organizations from developing and deploying biological weapons. 
For decades, research efforts on countermeasures against emerging infectious pathogens and 
biological warfare agents have been focused on attenuated or inactivated whole-bacteria or 
whole-virus vaccines. Despite their strong immunostimulatory efficacy, pre-clinical and clinical 
studies performed with these traditional vaccines have raised serious concerns, as they have 
induced unacceptable levels of reactogenicity and caused inadvertent pathogenic infections with 
ill-prepared live-cell vaccines in the past.2-4 In contrast, molecularly defined subunit antigens 
derived from whole pathogens offer safer alternatives. However, subunit antigens are usually far 
less immunogenic than live and attenuated vaccines and are also more susceptible to deactivation 
and degradation. Recent advances in particulate vaccine delivery systems have addressed these 
challenges faced by subunit antigen-based vaccines.5-8 In particular, various biomaterial-based 
particulate carriers have been shown to protect encapsulated antigens from enzymatic 
degradation, co-deliver antigens together with adjuvants to lymphatic organs, and prolong the 
stability of vaccine products without the infrastructure for cold-chain.9 Synthetic delivery 
systems such as poly(lactic-co-glycolic acid) (PLGA) microparticles, liposomes, and lipid-based 
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particles composed of FDA-approved materials have been intensely investigated by us and others 
for delivery of peptides, proteins, and DNA antigens.10-13 Use of biocompatible polymers and 
lipids can alleviate safety concerns often associated with viral vectors. Display of antigens on 
particle surfaces and formation of antigenic depots in situ can promote humoral immunity, 
characterized by robust, long-term, and balanced Th1/Th2 antibody responses.14, 15 Compared 
with soluble antigens which predominantly elicit humoral immune responses, particulate 
vaccines can enhance uptake and cross-presentation of antigens by dendritic cells and activate 
cytotoxic CD8+ T lymphocyte responses that are critical to eradicate intracellular infections.16-19 In 
addition, mucosal administration of nanoparticle vaccines can induce both mucosal and systemic 
immunity,20-23 thereby fortifying mucosal surfaces as the frontline of immunological defense 
against aerosolized bioterrorism agents or contaminated food and water supplies. 
This review is focused on particulate vaccine delivery systems developed against emerging 
infectious pathogens, including Category A (Table 1) and B agents (Table 2) as defined and 
classified by the U.S. CDC. Each agent/disease is introduced with basic pathological facts and a 
brief history of vaccination approaches, followed by an overview on research efforts to develop 
particulate vaccines. 
 
PARTICULATE VACCINES AGAINST CATEGORY A BIOTERRORISM AGENTS 
Category A agents include bacteria causing anthrax, plague, botulism, and tularemia as well as 
viruses leading to smallpox and viral hemorrhagic fevers. Although there are successful vaccines, 
perhaps best exemplified by the control and elimination of smallpox epidemic, vaccines for other 
causative pathogens in Category A are still in investigational status and are of the highest priority 
for biodefense research. To protect the general public from unpredictable events such as 
documented anthrax terror attacks and recent outbreaks of emerging infectious diseases, caused 
by Ebola virus and Zika virus, there is an urgent need to expedite pre-clinical development and 
clinical translation of promising vaccine candidates. Synthetic particulate systems for delivery of 
subunit antigens have been widely examined to potentiate both humoral and cellular immune 




Anthrax is an epizootic disease commonly affecting hoofed animals, and humans can also be 
infected upon contact with infected animals or their products. Anthrax is one of the most 
dangerous bioterror agents because spores of its pathogen, Bacillus anthracis, can survive for 
decades or even centuries under extreme temperature or chemical treatment and can be easily 
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aerosolized and disseminated.24 The threat of anthrax was realized by the 2001 U.S. postal attack 
that left five people killed and thousands exposed to the pathogen.25 To date, two prophylactic 
vaccines against anthrax have been developed. A live-spore vaccine was an effective formulation 
but often caused severe toxicity at injection sites; therefore, it has since been replaced by the 
current anthrax vaccine, AVA, registered as BioThrax®.26 AVA is produced by adsorbing the 
formalin-treated culture filtrates of a toxigenic but avirulent anthrax strain onto aluminium 
hydroxide. Although AVA can elicit robust humoral immune responses, it requires at least three 
initial vaccinations and yearly boosts for generation of long-term memory immune responses.24 
To address the limitations of current anthrax vaccines, subunit vaccines delivered by various 
particulate systems including polymeric nano/microparticles,27-30 nanoemulsions,31 and 
liposomes32 have been investigated and shown to improve the protective efficacy while reducing 
the number of administrations necessary to produce robust immune responses. In particular, the 
anthrax protective antigen (PA), which is a non-toxic, cell-binding component derived from the 
anthrax toxin, has been demonstrated to induce protection by elicitation of robust 
antigen-specific antibodies in both animal models and humans.33 A pilot study demonstrated that 
encapsulation or attachment of PA to poly-L-lactide (PLA) microparticles enhanced immune 
responses.27 When delivered through either the intramuscular or intranasal route, the vaccine 
particles protected all immunized mice against anthrax infection. In another approach, an 
intranasal vaccine was prepared by formulating PA with a water-in-oil nanoemulsion system, 
which elicited higher levels of mucosal anti-PA IgA and IgG than conventional adjuvants and 
conferred robust protection against an intranasal challenge with B. anthracis live spores (Figure 
1).31 Immunization of PA absorbed on aluminium hydroxide nanoparticles of ~0.1 μm in 
diameter increased the serum level of anti-PA IgG and reduced skin inflammation at the injection 
site, compared with vaccination with microparticles of ~10 μm.34 In addition to serving as 
adjuvants, particulate carriers can mediate co-delivery of antigen and danger signals, therefore 
amplifying immune responses. Intranasal immunization with chitosan nanoparticles co-loaded 
with PA and the adjuvant compound 48/80 achieved both mucosal and systemic humoral immune 
responses with a lower dose of PA, compared with soluble vaccines.29 Liposomes 
co-encapsulating PA and monophosphoryl lipid A (MPLA), a Toll-like receptor (TLR) 4 agonist, 
were shown to elicit higher levels of toxin-neutralizing antibodies, compared with PA adsorbed 
on Alhydrogel® or PA displayed on  bacteriophages.32 Interestingly, dextran microparticles 
co-encapsulating PA and resiquimod, a TLR 7/8 agonist, exhibited robust protective efficacy 
without raising high neutralizing antibody responses. Upon re-stimulation, splenocytes from 
immunized mice secreted high levels of IL-2 and IFN-³ ,30 suggesting that cellular immune 
responses may contribute to a successful anthrax vaccine. 
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Plague 
Plague, caused by infection with Yersinia pestis, is an ancient zoonotic disease that is naturally 
carried in rodent reservoirs. The disease can be transmitted to humans by direct contact with 
infected rodents or bites from inflected fleas from these rodents that cause bubonic plague, or by 
pathogenic aerosols that cause pneumonic plague. Historically, plague had been one of the most 
devastating epidemic diseases, including the infamous Black Death pandemic in the 14th century 
that killed one third of the European population. In particular, aerosolized Yersinia pestis can 
result in deadly pneumonic diseases with a mortality rate of 50-90% without treatment.35 
Although an intensive antibiotic therapy can reduce the mortality rate associated with pneumonic 
plague down to ~15%, it must be given within 24-36 h after exposure.35 In addition, there are 
reported cases of multidrug-resistant strains, raising concerns about antibiotic therapies.36 
Therefore, vaccine development against plague is an indispensable strategy for biodefense. Two 
types of plague vaccines have been used since the late 19th century: a killed whole-cell vaccine, 
which is only protective against bubonic plague, and a live whole-cell vaccine, which generates 
protective immunity against both bubonic and pneumonic plagues.2 However, both vaccines have 
been discontinued due to local and systemic side effects, such as regional lymphadenopathy, 
anorexia, and mild fever, long-term booster doses required, and safety concerns with the live 
bacterial vectors. Current research efforts have been mainly focused on the development of safer 
subunit vaccines utilizing the capsular subunit protein F1 and low-calcium response V antigen 
(LcrV). F1 and V, screened from a panel of key virulent factors from Yersinia pestis, have been 
reported to be promising antigens against bubonic and pneumonic plagues in various animal 
models.37 Polymeric microspheres have been tested as vaccine carriers to potentiate the efficacy 
of subunit plague antigens.38-40 PLA microspheres co-encapsulating F1 and V were shown to 
elicit superior humoral immune responses, compared with soluble vaccines irrespective of 
administration routes.38 A recent study on F1-loaded PLGA/PEG microspheres showed that a 
single vaccine dose was sufficient to protect mice from challenge.39 Nanoparticle delivery 
systems composed of poly(anhydride),41, 42 gold,43 lipoproteins,44 or a hybrid of lipids and 
biopolymers23 have been developed for plague vaccines. A single intranasal dose of recombinant 
F1-V-loaded poly(anhydride) nanoparticles led to prolonged lung disposition41 and generated 
high levels of antigen-specific antibody responses,42 with the overall kinetics dictated by the 
chemical composition, hydrophobicity, and degradation rate of poly(anhydride) particles.45 In 
another approach, F1 antigen was conjugated on the surfaces of gold nanoparticles via 
EDC/NHS chemistry, and the conjugates were resuspended in Alhydrogel®.43 This vaccine 
system elicited higher titers of both anti-F1 IgG1 and IgG2a than those elicited by the vaccine 
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without Alhydrogel® as well as the soluble F1 mixed with the adjuvant. Lipid-based delivery 
systems have also shown promising results for delivery of subunit plague antigens.23, 44 
Nanolipoprotein particles were constructed with lipids, cholate, and apolipoprotein that 
self-assembled into nanostructures mimicking high density lipoproteins (Figure 2A).44 V antigen 
was terminally modified with poly-histidine for complexation with nickel-modified lipids while 
MPLA or cholesterol-modified CpG was co-encapsulated via lipid insertion. The resulting 
vaccine particles significantly enhanced V-specific IgG titers in mice, compared with the 
physical mixture of V antigen and soluble or particulate adjuvants (Figure 2B). Recently, we 
have developed a lipid/biopolymer hybrid nanoparticle system, composed of cationic lipids and 
an anionic polymer hyaluronic acid, for intranasal delivery of F1-V (Figure 2C).23 Shielding of 
cationic liposomes with hyaluronic acid significantly reduced cytotoxicity of cationic lipids by at 
least 20-fold in dendritic cells. When administered via intranasal route in mice, the hybrid 
nanoparticles co-loaded with F1-V and MPLA generated potent humoral immune responses with 
11-, 23-, and 15-fold higher titers of anti-F1-V total IgG, IgG1, and IgG2c, respectively, and a 
more balanced Th1/Th2 response, compared with the soluble vaccine (Figure 2D). It remains to 
be seen how these lipid-based nanoparticles perform against pneumonic plague. 
 
Hemorrhagic fever caused by filoviruses and flaviviruses 
Filoviruses 
Filoviruses, including Marburg virus and Ebola virus, are the main causative pathogens for 
hemorrhagic fever in humans, which is a deadly disease transmitted by direct contact with 
infected subjects. Since their discovery in 1970s, several outbreaks resulted in fatality rates 
ranging from 25% to 90%. At the time of this writing, no vaccine or specific antiviral drug is 
available for the disease. The recent Ebola outbreaks in Africa have intensified research efforts to 
develop Ebola vaccines, resulting in two vaccine candidates, rVSV-EBOV and ChAd3-ZEBOV, 
both of which have entered Phase III trials as of late 2015.46 Historically, development of 
vaccines for Ebola began with inactivated whole viruses, and a whole virion inactivated by 
formalin was shown to provide better protection than the gamma-irradiation approach.47 More 
recently, a replication-defective whole-virus vaccine showed complete protection in a pilot trial 
on non-human primates.48 Given the variable potency of inactivated viruses and emergence of 
mutant strains, the primary vaccine approach has shifted from the direct use of whole virions to 
over-expression of genes encoding the Ebola glycoprotein (GP) and nucleoprotein (NP) in the 
host to elicit potent humoral and cellular immune responses. Specifically, immunity can be 
elicited by replication-deficient recombinant adenoviruses or plasmid vectors that transduce 
Ebola antigens or by attenuated recombinant viruses bearing Ebola GPs on their surfaces.49 
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However, booster immunizations are often required, and safety concerns remain for viral 
vectors.49 For instance, although recombinant vesicular stomatitis virus (rVSV) expressing Ebola 
GPs achieved complete protection under a “ring vaccination” scheme in a recent clinical trial,50 
previous pre-clinical studies in non-human primates have reported cases of vector-induced 
viremia;51, 52 thus, safety and compliance concerns need to be meticulously addressed in the 
ongoing clinical trials. As an alternative to the viral vector-based approaches described above, 
virus-like particles (VLPs) are the most promising vector-free vaccine platform in the 
pre-clinical pipeline for Ebola vaccines. Filovirus GPs along with a viral matrix protein VP40 
have been produced from mammalian cell lines and self-assembled into VLPs (Figure 3A).53 
Immunization with Ebola VLPs completely protected mice and non-human primates from a viral 
challenge (Figure 3B).54, 55 Follow-up studies revealed that the protection was dependent on type 
I interferons (IFNs),56 and VLPs combined with polyinosinic-polycytidylic acid (polyI:C),57 a 
TLR3 agonist capable of driving the production of type I IFNs, significantly augmented cellular 
and humoral immune responses (Figure 3C and D). In addition, a trimeric hybrid VLP was 
constructed to express GPs of the Marburg virus, Ebola Zaire and Sudan viruses.58 Immunization 
with these VLPs induced protection rates higher than 70% against a Marburg challenge but 
varying rates from 20% to 70% against an Ebola challenge depending on subunits of the Ebola 
GP used for the VLPs. In a separate line of studies, a liposomal formulation encapsulating 
irradiated Ebola virions and lipid A as adjuvant has been shown to elicit cytotoxic T-lymphocyte 
responses and achieve a protection rate of ~100% in a murine model; however, this liposomal 
vaccine failed to protect non-human primates from lethal challenge.59, 60 These results imply the 
daunting task of moving nanoparticle vaccines from small to large animal models, as various 
preclinical animal models exhibit different patterns of pathogenesis and susceptibility to a 
particular viral infection as well as varying degrees of immune responses elicited by vaccines. In 
addition, it remains to be seen how synthetic nanoparticles compare with widely explored VLPs 




In contrast to filoviruses that primarily infect primates, flaviviruses are naturally hosted in 
arthropods and only occasionally transmitted to humans by bites from infected mosquitoes or 
ticks. The pathogen family includes more than 70 different viruses, of which six agents are 
mainly responsible for disease burdens in humans: yellow fever virus, dengue virus, Japanese 
encephalitis virus, West Nile virus (WNVs), tick-borne encephalitis virus, and Zika virus.61 
Diseases caused by some of these agents have been controlled by successful live-attenuated or 
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killed whole-virus vaccines.62 In particular, the first tetravalent dengue vaccine that provides 
protection against all four dengue virus serotypes has been approved in Mexico, Philippines, and 
Brazil in December 2015.63, 64 However, there are currently no effective therapeutic interventions 
or prophylactic vaccines against WNV. To address the shortage of available vaccines, particulate 
platforms have been developed for vaccine delivery of WNV antigens. One study has compared 
immune stimulatory effects elicited by gold nanoparticles of different sizes and shapes and 
coated with WNV envelope protein antigen on their surfaces.65 Although rod shape particles 
were most favorable for antigen uptake by macrophages and dendritic cells, 40-nm spherical 
gold nanoparticles elicited the highest titer of antigen-specific antibodies, which were 2-fold 
greater than those induced by gold nanorods. In another approach, PLGA nanoparticles were 
used to encapsulate WNV envelope protein in the particle core and display CpG on particle 
surfaces.66 Compared with Alhydrogel® which predominantly drove Th2 responses, the 
nanoparticle vaccine skewed humoral immune responses to the Th1 type, eliciting 
antigen-specific cellular immunity, and protecting 94% of animals against a viral challenge in 
mice. These studies highlight promising engineering approaches of delivery carriers to effective 
particulate vaccines against WNV. 
On the other hand, Zika virus first discovered in 1950s has received little attention67 and 
remained as one of the neglected tropical diseases without any research effort devoted to the 
vaccine development until the recent outbreak in Brazil. As of this writing, the World Health 
Organization has declared an international public health emergency on the ongoing Zika virus 
outbreak that is now spreading throughout Latin America. Zika infection can easily spread 
through mosquito bites, and there is also a report of suspected transmission by sexual 
intercourse.68 While Zika infection does not trigger perceivable symptoms in infected hosts, it 
may endanger fetus development in pregnant women, causing infant microcephaly birth 
defects.69 This has prompted world leaders to devote more resources to research on vaccine 
development and diagnostics as well as disease control and public preparedness to combat 
against the global health threat. 
 
Botulism 
The botulinum toxin, produced by Clostridium botulinum, triggers neuroparalytic diseases and is 
regarded as one of the most lethal poisons.70 The disease can occur due to accidental food 
poisoning or inhalation of maliciously dispersed bacterial spores.71 Interestingly, the toxin can 
also be used to treat neurological disorders such as dystonia when locally injected at an 
appropriate dose.70 Formalin-inactivated toxoid vaccines have been developed previously, 
including a pentavalent vaccine registered as an Investigational New Drug in the US.3, 71 
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However, this vaccine was discontinued in 2011 due to declining potency and increasing 
reactogenicity following annual boosts, and currently there is no botulism vaccine available.3 For 
vaccination with a non-toxic subunit of the botulinum toxin, an adjuvant-free nanogel system has 
been prepared by self-assembly of polysaccharide pullulan modified with cholesteryl and amino 
groups (Figure 4A).72 Compared with a soluble vaccine, the nanogel significantly increased the 
residence time of antigen in nasal epithelium upon intranasal vaccination (Figure 4B) and 
elicited robust antigen-specific mucosal IgA and systemic IgG responses (Figure 4C), achieving 
complete protection of animals against an intraperitoneal or intranasal challenge with 
Clostridium botulinum neurotoxin (Figure 4D). Apart from these studies, there have been only 
limited research efforts for vaccine development against botulinum toxin. Given the promising 
results presented here, nanoparticle-based vaccine approaches warrant further investigations. 
 
Tularemia 
Tularemia is caused by Francisellar tularensis which infects both animals and humans. There are 
various pathogenic strains that can cause ulceroglandular, gastroinstestinal, oropharyngeal, or 
pneumonic tularemia.4 Similar to plague, the pneumonic form of tularemia poses the highest 
public health risk and is the major concern for bioterrorism due to its low lethal dose, high 
virulence, and ease of aerosol dissemination. Although an attenuated live vaccine strain (LVS) 
was developed for vaccination, it has been terminated due to potential safety issues associated 
with pathogenic mutations of the vaccine strain and unsatisfactory efficacy.4 Particulate delivery 
approaches for tularemia vaccines have been mostly focused on lipid-based nanoparticles and 
have offered some initial success. In one example, vaccination with synthetic liposomes 
incorporating the membrane proteins of LVS and alum plus IL-12 protected mice against a LVS 
challenge but not against the virulent strain.73 In another study, bacterial lysates were loaded into 
catanionic vesicles formed by surfactants with opposite charges.74 Immunized mice were 
completely and partially protected from challenge with LVS and a virulent strain, respectively. 
Transferring the immune sera into naïve mice also protected recipients against a LVS challenge, 
indicating the importance of humoral immunity. In addition, archaeal lipids have been tested as 
an adjuvant for LVS lysates.75 Intranasal immunization with this vaccine elicited high 
antigen-specific antibody titers in serum and bronchial lavage fluids as well as cellular immune 
responses, characterized by the proliferation of antigen-specific splenocytes and IL-17 secretion. 
In fact, cellular immunity directed against intracellular Francisellar tularensis may play a vital 
role in vaccination against tularemia as the bacteria can evade phagocytic degradation and reside 
within macrophages.76, 77 As demonstrated by these studies, it is relatively easy to show the 
protective efficacy of vaccines against LVS. Future studies should be directed to enhance 
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immunogenicity of particulate vaccines and assess their potency in more stringent animal models 
utilizing virulent strains of Francisellar tularensis. 
 
PARTICULATE VACCINES AGAINST CATEGORY B BIOTERRORISM AGENTS 
Category B agents are of the second highest priority due to their moderate ease of dissemination, 
morbidity, and mortality. Several pathogens of this category, including salmonellosis, shigellosis, 
and cholera, are mainly transmitted by the fecal-oral route. Although their natural outbreaks can 
be prevented by improving hygiene resources in epidemic areas, prophylactic vaccines are 
needed for protection against malicious dissemination by aerosolized pathogens or contaminated 
food and water supplies. Particulate vaccines investigated for Category B agents are summarized 
in Table 2. 
 
Brucellosis 
Brucellosis is a zoonosis that mainly infects livestock, such as cattle, swine, and goats. 
Brucellosis is caused by gram-negative Brucella species, among which B. melitensis causes the 
most severe disease with frequent debilitating relapses.78 Brucella is transmitted to humans by 
fluid discharges from infected animals, especially dairy products, or by aerosol dissemination.79 
Although Brucellosis is currently controlled by vaccination of susceptible livestock, these 
veterinary vaccines are pathogenic to humans.80 Several attenuated Brucella strains and extracted 
bacterial fractions have been used as vaccines in humans in the last century. However, none of 
these are in use nowadays due to suboptimal efficacy.81 To remedy these issues, many particulate 
delivery systems have been examined. In one study, a hydrophobic portion of the bacterial 
extract was encapsulated in microparticles composed of poly (ε-caprolactone), β-cyclodextrin, 
and Pluronic F68.82 This vaccine protected mice against B. melitensis challenge with a similar 
efficacy as the live attenuated vaccine. In another study, subcellular bacterial extracts were 
loaded in poly(anhydride) nanoparticles modified with mannose and delivered via the ocular 
route to target the mucosal immune system.83 A single vaccination dose achieved higher IgA 
titers and improved protection, compared with the live attenuated vaccine. Since Brucella species 
predominantly reside in macrophages and monocytes, cellular immunity, supported by the killing 
of infected cells by cytotoxic CD8+ T lymphocytes and secretion of Th1 cytokines by CD4+ T 
cells, was shown to be vital for elimination of the bacteria.78, 84 In order to amplify cellular 
immunity against Brucella, a subunit nucleoprotein or T-cell epitopes derived from the bacteria 
have been encapsulated in PLGA microparticles. Although these particles offered protection 
against virulent Brucella infection, their efficacy was suboptimal compared with the live 
attenuated vaccine.85, 86 Hence, future studies should be devoted to developing particulate 
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systems capable of eliciting potent, concerted humoral and cellular immune responses against 
Brucellosis. 
 
Food safety threats 
Salmonellosis 
The gram-negative bacterium Salmonella, especially S. enterica, is an enteric pathogen and a 
common cause of food-borne diarrheal illness. Four serovars of S. enterica, namely Typhi, 
Paratyphi A, Typhimurium, and Enteritidis, are responsible for severe infections in humans, with 
the former two types causing enteric fever and the latter two types causing the invasive 
nontyphoidal Salmonella (iNTS) disease.87 Every year there are 21.7 million cases of infection 
and 200,000 fatalities due to typhoid fever from Typhi infection.88 Current vaccines against 
Salmonella are limited to the Typhi serotype, and they include an inactivated whole-cell vaccine, 
a live-attenuated vaccine made of a mutant strain Ty21a, and a subunit vaccine made of Vi 
polysaccharide.89 Among these, the whole-cell vaccine has achieved the highest three-year 
cumulative efficacy of 73%; however, high reactogenicity limits its general use.87 Ty21a and Vi 
polysaccharide vaccines have protection rates of ~50% with reduced adverse reactions, but 
neither is suitable for infants, who suffer most from the disease.87, 90 In addition, the emerging 
antibiotic-resistant strains provide further motivation for the development of new vaccine 
products.91 Particulate delivery systems have been examined to improve the efficacy of subunit 
Salmonella vaccines. Subcellular extracts from the Enteritidis serovar were encapsulated into 
nanoparticles composed of copolymer poly(methyl vinyl ester/maleic acid) (PVM/MA).92 The 
particulate formulation elicited robust IFN-³  release from splenocytes in immunized mice and 
completely protected animals against a lethal challenge. In another study, Vi polysaccharide 
delivered by PLA nanoparticles or microparticles induced higher levels of antigen-specific IgG 
and memory antibody responses than a soluble vaccine.93 Furthermore, high density of antigens 
displayed on the surfaces of PLA particles correlated with robust humoral immune responses. 
These results suggest that engineering of the interface between antigen-displaying vaccine 
particles and B-cells is crucial to prime strong humoral immunity. In addition, particulate 
delivery of compiled subunit antigens for individual serotypes or a common subunit, e.g. a 




The enteric pathogen Shigella, which is usually transmitted by the fecal-oral route, is another 
major cause of diarrhea. Four Shigella species have been identified to date: S. dysenteriae, S. 
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flexneri, S. sonnei, and S. boydii, among which the first three are more common for human 
enteric diseases.94 Specifically, the invasive S. dysenteriae Type 1 causes dysentery and 
life-threatening kidney damage by releasing Shiga toxin.95 Currently, there is no vaccine 
available for Shigellosis, but several vaccine candidates are undergoing clinical trials.95 Due to 
their favorable safety profiles, subunit vaccines are ideal alternatives to live-attenuated vaccines, 
as vaccine safety is of the utmost importance for Shigella vaccines as children under 5 years old 
are most vulnerable to Shigellosis.96 In one approach, outer membrane vesicles (OMVs) from S. 
flexneri have been encapsulated into nanoparticles made of copolymer PVM/MA as a subunit 
vaccine.97, 98 After intradermal, oral, or intranasal immunization, the vaccine nanoparticles 
completely protected mice against a pathogen challenge. Notably, future studies should be 
directed to optimize particulate delivery systems for mucosal vaccination against Shigella as 
such strategy may offer a key advantage to effectively stop its transmission at mucosal surfaces. 
 
Escherichia coli O157:H7 
Although the majority of E. coli strains are benign inhabitants in the human gastrointestinal tract, 
enterohemorrhagic E. coli strains, which produce the Shiga toxin (Stx), can cause diarrheal 
illness, even hemorrhagic colitis, and hemolytic uremic syndrome.99 E. coli O157:H7 is the 
predominant serotype responsible for frequent outbreaks.100 Cattle are the natural host of E. coli 
O157:H7, and humans can be infected by consumption of contaminated meat.101 Although 
vaccines for cattle are used to control the disease transmission,102 it is difficult to eliminate the 
human disease burden due to other animal and environmental reservoirs of the pathogen.101 To 
develop vaccines for human use, liposomes have been investigated as a vaccine carrier for either 
the whole bacteria or subunit bacterial proteins. Killed bacteria along with adjuvant MPLA have 
been co-incorporated into liposomes to produce an oral vaccine, which elicited both systemic and 
mucosal IgA and IgG antibodies specific to the pathogen.103 Alternatively, Stx was conjugated to 
amine-modified liposomal surfaces via glutaraldehyde-mediated reaction, which also inactivated 
the toxin during the coupling process.104 This liposomal vaccine induced robust antigen-specific 
serum IgG titers and conferred protection against an intravenous toxin challenge in both murine 
and non-human primate models.104, 105 Recently, a novel anti-bacterial vaccine approach has been 
developed by coating OMVs on nanoparticle templates.106 OMVs derived from a model 
pathogen Escherichia coli were stably coated on the surfaces of gold nanoparticles which 
enhanced activation of dendritic cells, elicited higher serum titers of antigen-specific IgG, and 
robust cytokine secretion from splenocytes after a single subcutaneous injection in mice, 
compared with vaccination with native OMVs. 
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Staphylococcal toxins 
Staphylococcal toxins, especially staphylococcal enterotoxin B (SEB) secreted by the 
gram-positive bacterium Staphylococcus aureus, are a common cause of food poisoning,107  
while inhaled SEB provokes more serious syndromes. SEB is a “superantigen” that can lead to 
hyper T-cell activation and “cytokine storm”, characterized by massive secretion of TNF-±, 
IFN-γ, IL-1, IL-2, and IL-6.108 Initial attempts to develop SEB vaccines were focused on the 
formalin-inactivated toxin and recombinant mutant strains, but there are still no agents available 
to protect against SEB or treat SEB intoxication.109 To address these challenges, PLGA particles 
have been used to deliver inactivated SEB.110, 111 When multiple routes of vaccine delivery were 
tested with PLGA microparticles, an intratracheal booster dose offered the highest rate of 
protection in monkeys against a challenge with aerosolized SEB, compared with the 
intramuscular or oral route of vaccination.110 Inactivated SEB delivered by PLGA nanoparticles 
also elicited humoral immune responses comparable to those elicited by a vaccine formulation 
with alum.111 In an alternative approach, staphylococcal α-haemolysin was trapped by 
erythrocyte membranes coated on the surfaces of PLGA nanoparticles (Figure 5A).112 Compared 
with heat-inactivated toxin, this nanotoxoid vaccine alleviated toxicity at injection sites while 




The gram-negative bacterium Vibrio cholerae is transmitted to humans most often by 
contaminated drinking water and causes the acute diarrheal disease cholera.113 V. cholerae has 
been classified into more than 200 serogroups according to different O antigens of the bacterial 
lipopolysaccharides (LPS), and only O1 and O139 strains are known to cause epidemic 
cholera.114 Currently there are three oral vaccine products available: Dukoral®, mORC-Vax™, 
and Shanchol™.115 However, these vaccines require a booster dose, provide only limited and 
short-term protection, and are not suitable for children under two years old.114, 115 Therefore, their 
use is mainly restricted to travelers rather than the general population in endemic areas.116 
Polymeric particles have been intensely investigated as a delivery system for cholera vaccines.117 
A mutant V. cholerae strain was efficiently loaded into PLGA microparticles with encapsulation 
efficiency of ~98%.118 The particulate vaccine administered orally elicited higher humoral 
immune responses than a soluble vaccine, and the addition of an anti-fungal drug, amphotericin 
B, as an adjuvant further enhanced the immune responses. Another study compared the efficacy 
of whole-bacterium vaccine formulated into polymeric microparticles composed of PLGA 
(50:50), PLGA (75:25), or PLA/PEG copolymer.119 Those particulate vaccines showed similar 
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size distribution, encapsulation efficiency, and in vitro release profiles of the encapsulated 
antigen. Upon oral immunization in mice, the PLA/PEG formulation elicited the highest 
antigen-specific IgG, IgA, and IgM titers and a superior survival rate post-challenge. In an 
alternative approach, an oral cholera vaccine was produced by encapsulating inactivated V. 
cholerae into microparticles composed of the enteric excipient Eudragit® and mucoadhesive 
agents alginate or Carbopol®.120, 121 Following oral vaccination, the formulation incorporating 
alginate elicited higher vibriocidal titers than a soluble vaccine, demonstrating the promise of 
mucoadhesive particles for oral vaccination against cholera. 
 
Melioidosis and glanders 
Burkholderia pseudomallei and Burkholderia mallei are the causative agents of melioidosis and 
glanders, respectively. Both pathogens are gram-negative bacteria that reside in host immune 
cells and establish infection after oral ingestion, aerosol inhalation, or skin contact with 
cutaneous wounds.122 Melioidosis is a severe human endemic disease in Southeast Asia and 
Northern Australia, with mortality rates of 50% and 20%, respectively.123 In contrast, glanders 
mainly infects solipeds, such as horses, mules, and donkeys, but rarely infects humans.124 
Although it is reported that glanders has been eradicated in the developed world, it still poses a 
threat to public health, and B. mallei has a documented history as a bio-warfare agent.125 In 
addition, both pathogens are resistant to most antibiotics, and there is no vaccine product 
available.125, 126 Early vaccine approaches include live-attenuated or inactivated bacteria and 
subunit vaccines for both diseases; however, none have achieved complete protection.122 Since 
an intracellular cycle is indispensable for the infectivity of these pathogens, induction of cellular 
immune responses by specific adjuvants are of particular interest. For instance, pre-treatment 
with CpG, a TLR9 agonist, has been shown to promote protection against B. pseudomallei.127 
Furthermore, CpG complexed with cationic DOTAP liposomes showed better protection than 
CpG complexed with zwitterionic DOPC liposomes or soluble CpG.128 The CpG/DOTAP 
vaccine delivered intranasally in mice conferred partial protection against a lethal challenge of B. 
mallei or B. pseudomallei, and the protection relied on an elevated level of IFN-³  and activation 
of NK cells, suggesting the important roles of adaptive and innate immune responses in disease 
control.129 However, mice protected from the acute challenge still developed chronic infections 
in spleen and liver. Recently, a subunit particulate vaccine has been developed for B. mallei by 
conjugating LPS from a non-virulent strain to the surfaces of gold nanoparticles.130, 131 
Vaccinated mice were later challenged with aerosolized B. mallei. Compared with the soluble 
LPS, the nanoparticle vaccine elicited higher anti-LPS IgG titers, reduced bacterial burdens in 
the spleen, and enhanced protection.130 However, when tested in non-human primates, the 
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vaccine failed to induce favorable protection compared with non-immunized controls, despite 
elicitation of anti-LPS IgG.131 
 
Ricin toxin 
Ricin toxin is derived from the common plant Ricinus communis, or castor beans, and can be a 
byproduct during the production of castor oil. Despite multiple routes that can induce poisoning, 
ricin toxin is rarely transmitted to humans, and interpersonal transmission is negligible.132 
Nevertheless, ease of production, storage, and dissemination, as well as the lack of effective 
protective and therapeutic options still make ricin toxin a potential bioterror threat.133 Indeed, it 
has been utilized in espionage incidents and malicious mailing attacks.134, 135 Ricin toxin is a 
heterodimeric glycoprotein consisting of an A chain (RTA) which enzymatically inactivates 
ribosomes, and a B chain (RTB) which facilitates entry of the toxin into target cells.136 Since 
RTB is a poor inducer of humoral immune responses, inactivated forms of the toxin and RTA 
become the main antigen sources tested for vaccine development.109, 133 In one approach, a single 
subcutaneous immunization of PLGA microparticles encapsulating the inactivated toxin induced 
similar serum levels of anti-ricin IgG and protection rates as three doses of a soluble vaccine.137 
Notably, humoral immune responses elicited by the particulate vaccine lasted as long as one year 
after immunization. In a follow-up study with single or dual doses delivered through the 
intranasal route, the microparticle vaccine elicited higher serum anti-ricin IgG and IgA titers and 
achieved a higher protection rate against an aerosol challenge, compared with the soluble 
vaccine.138 The enhanced protection was observed when the challenge was performed at six 
weeks or one year after immunization. As an alternative strategy, liposomes encapsulating the 
inactivated toxin have been examined for intratracheal delivery.139, 140 The liposomal vaccine 
elicited similar humoral immune responses and slightly better short-term protection against an 
aerosol challenge, compared with soluble vaccines with or without the Alhydrogel® adjuvant.140 
Further pathological analyses post-challenge revealed that the liposomal vaccine reduced 
infiltration of neutrophils into lungs and decreased pulmonary edema.141 
 
Viral encephalitis caused by alphaviruses 
Encephalitic alphaviruses, including eastern equine encephalitis virus (EEEV), western equine 
encephalitis virus (WEEV), and Venezuelan equine encephalitis virus (VEEV), infect both horses 
and humans in an epidemic area restricted to the Americas.142 The mortality rates are 3-7% for 
WEEV and 50-75% for EEEV, and there are no available therapeutics or vaccines.143, 144 Both 
attenuated and formalin-inactivated vaccines have been tested for three encephalitic alphaviruses, 
but none of the candidates were viable due to high reactogenicity of the attenuated vaccines and 
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poor efficacy of the inactivated vaccines.144 To improve the efficacy, inactivated VEEV was 
encapsulated into PLGA microparticles and delivered via multiple routes.145 Mice were 
immunized through the subcutaneous or intratracheal route, followed by a booster dose through 
the oral, subcutaneous, or intratracheal route. The intratracheal route elicited mucosal anti-VEEV 
IgG and IgA with higher activity and also enhanced protection, compared with the other two 
routes tested for the booster dose. 
 
Conclusion 
Most particulate delivery systems examined in the past for biodefense vaccines are composed of 
biodegradable materials, such as PLGA and phospholipids, which are already approved for 
pharmaceutical products and would therefore facilitate clinical translation of promising vaccine 
candidates. Particulate vaccine vehicles can stably encapsulate or surface-display antigens while 
also serving additional roles as adjuvants or carriers for adjuvant molecules. As shown in studies 
discussed above, successful seroconversion usually correlates with high protection rates against 
lethal challenges, while cellular immunity is vital for elimination of intracellular reservoirs of 
pathogens. 
It is the authors’ opinion that more resources and research efforts should be devoted to the 
development of mucosal vaccine delivery systems for biodefense vaccines. Mucosal vaccination 
would preferentially elicit T- and B-cell immune responses in local and distal mucosal surfaces, 
including the respiratory tract, thereby establishing immunity in the frontline of protection 
against aerosol transmission of bioterrorism agents.20-23 Compared with soluble antigens that are 
subjected to fast clearance or degradation, particulate vaccines could improve colloidal stability, 
increase residence time in mucosal tissues, and promote induction of antigen-specific IgA titers 
and peripheral tissue-resident effector CD4+ and CD8+ T-cells. Among various mucosal delivery 
strategies, oral vaccines may be most amenable to mass vaccination campaigns in the event of 
biological terror attacks and also most efficacious for immunization against enteric pathogens.146 
Indeed, oral vaccine delivery has been exploited for currently licensed and candidate cholera 
vaccines. However, one of the major challenges in oral vaccination lies in rapid denaturation and 
degradation of antigens in response to acidic pH and abundant proteases in the gastrointestinal 
tract. Thus, it would be valuable to investigate particulate carriers composed of biopolymers that 
can endure the harsh gastric environment or liposomes stabilized by bile salts or archaeobacterial 
lipids that can maintain antigenicity and immunogenicity of antigens.147 In addition, vaccine 
carriers targeted to M cells and/or intestinal dendritic cells should be examined to further 
improve the efficiency of oral vaccination. Another mucosal route of vaccine delivery that 
warrants further investigation is transcutaneous vaccination. Notably, microneedle patches have 
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recently garnered much attention as a promising vaccine delivery tool that could offer good 
patient compliance and facile self-administration approaches, while achieving dose sparing by 
targeting of antigens and adjuvants to skin-resident antigen-presenting cells.148-150 As in the case 
with oral dosage forms, pre-formulated microneedle patches could be easily stored for long-term 
preparedness and rapid distribution among susceptible populations in response to bioterror 
attacks. New microneedle technologies permit long-term storage of vaccines and allow precise 
tuning of drug release profiles by employing dissolvable polymeric patches,151 layer-by-layer 
coatings on needles,152 or therapeutic depots responsive to external tensile strength.153 Future 
research efforts should be directed to exploit these technologies to achieve efficient and stable 
loading of antigens, to attract skin-resident DCs to vaccination sites with the antigen depot 
deployed during administration, and to augment mucosal immune responses. These advances 
will allow an unprecedented control over dosing and immunization schemes for transcutaneous 
vaccination. 
There are numerous challenges that need to be overcome for clinical translation of 
particulate vaccines against biological warfare agents. It is crucial to streamline the 
manufacturing processes for industrial scale-up of particulate vaccines with minimal 
batch-to-batch variability. In addition, since large vaccine stockpiles and rapid and facile 
distribution of vaccines are vital components of countermeasures against outbreaks and bioterror 
attacks, it is critical to develop vaccine products that are stable for a long term without the 
cold-chain. Furthermore, as illustrated in this article, the majority of particulate vaccine 
candidates is still in the early stages of pre-clinical development and tested only in murine 
models. However, many vaccine candidates that may be adequate in small animals fail to exhibit 
strong immune responses in large animals or humans. Murine species cannot be naturally 
infected by many emergent pathogens introduced above. The pathogenesis, dosing for 
immunization and challenge, and types and durability of immune responses demonstrated in 
murine models may not correlate with those in natural hosts, including humans. Furthermore, 
following the disease challenge, small animals may clear pathogens by one-wave immune 
responses or easily succumb to death, making them inappropriate models to evaluate vaccine 
efficacy against latent intracellular infections or recurring and debilitating diseases.154, 155 
Therefore, more stringent screening process should be implemented in the early cycles of 
product development; this may involve direct comparison of particulate vaccine candidates 
against other strong benchmarks in vaccine research, including gold standard adjuvants, VLPs, or 
live vectors. In parallel, evaluation of vaccine candidates in more rigorous animal models, 
including non-human primates, should be considered early in the vaccine design and 
development. 
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In conclusion, particulate delivery systems have shown great promise for addressing current 
limitations in vaccine technologies against bioterrorism and emerging infectious agents, and they 
should be strongly considered for public health preparedness and countermeasures against 
potential outbreaks and bioterror threats. 
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Figure 1. A nanoemulsion (NE) system formulated with the anthrax protective antigen (PA) 
enhanced mucosal humoral immune responses and improved protection against bacterial spore 
challenges. Compared with conventional adjuvants, such as MPLA, CpG, and aluminium 
hydroxide, the NE vaccine administered via the intranasal route elicited higher titers of anti-PA 
IgA (A) and IgG (B) in bronchial alveolar lavage fluids from immunized mice. Vaccination with 
the NE vaccine also protected guinea pigs against an intranasal challenge with a 10-fold (C) or 
100-fold (D) LD50 dose of bacterial spores. Reproduced with permission from ref. 
31. 
 
Figure 2. Lipid-based nanoparticles for delivery of subunit plague antigens. (A) A 
nanolipoprotein particle loaded with adjuvants and LcrV modified with poly-histidine. (B) 
Co-delivery of LcrV and adjuvants via the intraperitoneal route elicited higher anti-LcrV IgG 
titers than LcrV admixed with or without soluble or particulate adjuvants. (C) A cationic 
lipid/hyaluronic acid (HA) hybrid nanoparticle formed by cross-linking of thiolated HA and 
thiolated polyethylene glycol (PEG). (D) Intranasal vaccination with the hybrid particles 
co-loaded with F1-V and MPLA elicited significantly higher serum titers of anti-F1-V IgG, 
compared with the soluble mixture of F1-V and MPLA. (A) and (B) reproduced with permission 
from ref. 44; (C) and (D) reproduced with permission from ref. 23. 
 
Figure 3. Virus-like particles (VLPs) as an Ebola vaccine candidate. (A) Transmission electron 
microscope images of Ebola viruses (left) and VLPs (right). (B) Mice were immunized three 
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times with Ebola VLPs (eVLPs), inactivated Ebola viruses (iEBOV) or Marburg viruses 
(iMARV), or PBS, followed by a challenge with the mouse-adapted Ebola virus. (C) and (D) 
Humoral and cellular immune responses elicited by Ebola VLPs were augmented by polyI:C. (C) 
A low dose of VLPs along with 100 ng-100 μg polyI:C elicited high serum titers of 
antigen-specific IgG. (D) Splenocytes from immunized mice were cultured with Ebola GP, 
followed by stimulation with an Ebola GP peptide in vitro. Robust effector T cells were induced 
by immunization with 10 μg VLPs and polyI:C. (A) and (B) reproduced with permission from 
ref. 54; (C) and (D) reproduced with permission from ref. 57. 
 
Figure 4. A cationic nanogel developed for intranasal delivery of a subunit botulism neurotoxin. 
(A) The nanogel was self-assembled by the polysaccharide pullulan modified with cholesteryl 
and amino groups. Intranasal immunization with antigen-loaded nanogels significantly enhanced 
nasal residence of the antigen (B), antigen-specific antibody titers (C), and protection against 
challenge with the neurotoxin (D), compared with the soluble antigen. Reproduced with 
permission from ref. 72. 
 
Figure 5. Erythrocyte membrane-coated PLGA nanoparticles for vaccine delivery of 
staphylococcal α-haemolysin (Hla). (A) Schematic illustration and an image by transmission 
electron microscope of the nanotoxoid. Scale bar, 80 nm. (B) The nanotoxoid vaccine enhanced 
humoral immune responses and protected mice against toxin challenge. Empty triangles, vaccine 
particles without the antigen; solid triangles, unvaccinated control; blue squares, single dose of 
the heat-inactivated Hla; blue spheres, single dose of the nanotoxoid; red squares, three doses of 
the heat-inactivated Hla; red spheres, three doses of the nanotoxoid. Reproduced with permission 




















This article is protected by copyright. All rights reserved.
Table 1. Particulate Vaccine Delivery Systems Investigated for Category A Bioterrorism Agents. 
Disease Antigen Delivery System Adjuvants Animal Model Dosing Scheme Major Results Ref. 
Anthrax PA PLA microparticle None Mice i.m. or i.n., two 
doses 
Complete protection mediated by robust levels of anti-PA 
IgG 
27 
 A subunit of PA PLGA nanoparticle None Mice i.p., single dose Balanced Th1/Th2 humoral immune responses; prolonged 
survival compared with a soluble vaccine 
28 
 PA Nanoemulsion None Mice, guinea 
pigs 
i.n., two doses More than 3-fold higher anti-PA IgG and IgA titers than 
vaccines composed of other adjuvants including MPLA, 
CpG or Alum; protection rates of 70% and 40% following 
a low and high dose of pathogen challenge, respectively 
31 
 PA Chitosan nanoparticle Compound 48/80 Mice i.n., three doses Enhanced mucosal and systemic humoral immune 
responses compared with soluble vaccines 
29 
 PA Liposome MPLA Rabbits i.m., two or three 
doses 
Complete protection mediated by robust levels of 
neutralizing antibodies 
32 
 PA Dextran microparticle Resiquimod Mice s.c., two doses Complete protection possibly by cellular immune 
responses 
30 
 PA Aluminum nanoparticle None Mice s.c., two doses Durable anti-PA IgG titer for a month after the booster 
dose; enhanced antigen uptake, and milder inflammation at 
the injection site compared with the microparticle 
counterpart 
34 
Plague F1 and LcrV PLA microparticle None Mice i.t., i.m., or i.n., 
two doses 
Successful elicitation of antigen-specific antibodies 38 
 F1 PLGA/PEG 
microparticle 
None Mice s.c., single dose Complete protection mediated by robust anti-F1 IgG titers 39 
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 B- and T-cell 
epitopes of LcrV 
PLGA microparticle None Mice i.n., single dose Balanced Th1/Th2 responses; protection rates varied 
between 0-90% depending on epitope sequences 
40 
 F1-V Poly(anhydride) 
nanoparticle 
None Mice i.n., single dose Complete protection mediated by high avidity, 
antigen-specific IgG 
42 
Table 1 (Continued)        
Disease Antigen Delivery System Adjuvants Animal Model Dosing Scheme Major Results Ref. 
Plague F1 Gold nanoparticle Alhydrogel® Mice s.c., single dose Two- to four-fold higher titers and avidity of anti-F1 IgG 
than those elicited by a soluble vaccine or the particulate 
vaccine without adjuvant 
43 
 LcrV Lipoprotein nanoparticle MPLA or CpG Mice i.p., single dose Four-fold higher anti-V IgG titer than that elicited by 
soluble vaccines 
44 
 F1-V Cationic lipid/hyaluronic 
acid hybrid nanoparticle 
MPLA Mice i.n., three doses Enhanced biocompatibility and 11-fold increase in serum 




caused by filoviruses 
Irradiated whole 
Ebola virus 
Liposome MPLA Mice, NHP i.v. or i.m., two 
doses 
Elicitation of cytotoxic T-lymphocyte responses; complete 
protection was achieved in the murine but not the NHP 
model 
59, 60 
 Ebola GP and 
VP40 
VLP None Mice i.m. or i.p., three 
doses 
Activation of dendritic cells in vitro; elicitation of cellular 
and humoral immune responses in vivo; complete 
protection 
54 
 Ebola GP, NP, and 
VP40 
VLP Ribi adjuvant NHP i.m., three doses Elicitation of humoral and cellular immune responses; 
complete protection 
55 
 Ebola GP, VLP Poly I:C Guinea pigs Unknown route, The protection rate against a Marburg viral challenge was 58 
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Marburg GP, and 
VP40 
two doses higher than 70%; protection rates against an Ebola viral 
challenge varied between 20%-70% for Ebola GP subunits 
with different immunogenicity 
Hemorrhagic fever 
caused by flaviviruses 
WNV envelope 
protein 
Gold nanoparticles of 
different sizes and 
shapes 
None Mice i.p., two doses Rod-like particles facilitated antigen uptake by 
antigen-presenting cells, whereas 40-nm nanospheres 
elicited the highest levels of antigen-specific antibodies 
and inflammatory cytokines in vivo 
65 
 WNV envelope 
protein 
PLGA nanoparticle CpG Mice s.c., two doses Th1-skewed humoral immune responses; a protection rate 
of 94%. 
66 
Table 1 (Continued)        
Disease Antigen Delivery System Adjuvants Animal Model Dosing Scheme Major Results Ref. 
Botulism Subunit of the 
botulinum toxin 
Pullulan nanogel None Mice i.n., single dose Prolonged nasal residence of the antigen within 12 h post 
immunization; robust titers of antigen-specific mucosal 
IgA and systemic IgG; complete protection 
72 
Tularemia Membrane 
proteins of LVS 
Liposome IL-12 and Alum Mice s.c, i.p., or i.n., 
three doses 
Complete protection against LVS but not a virulent strain 73 
 LVS lysates Catanionic vesicle None Mice s.c, i.p., or i.n., 
two to four doses 
Protection rates were 100% and < 25% against LVS and a 
virulent strain, respectively 
74 
Abbreviations: PA, the protective antigen of Bacillus anthracis; PLA, poly-L-lactide; PLGA, poly(lactic-co-glycolic acid); PEG, polyethylene glycol; LcrV: low-calcium response V antigen of Yersinia 
pestis; F1-V, recombinant protein of capsular portion F1 and LcrV of Yersinia pestis; MPLA, monophosphoryl lipid A; LVS, live vaccine strain of attenuated Francisellar tularensis; GP, glycoprotein; 
NP, nucleoprotein; VP40, viral matrix protein 40 of filoviruses; VLP, virus-like particle; poly I:C, polyinosinic-polycytidylic acid; NHP, non-human primate; WNV, West Nile virus; i.m., intramuscular; 
i.n., intranasal; i.p., intraperitoneal; s.c., subcutaneous, i.t., intratracheal; i.v., intravenous. 
 
 














Table 2. Particulate Vaccine Delivery Systems Investigated for Category B Bioterrorism Agents 
Disease Antigen Delivery system Adjuvants Animal Model Dosing Scheme Major Results Ref. 
Brucellosis Subcellular extraction PCL microparticle None Mice s.c., single dose Similar protection efficacy as a live attenuated 
vaccine 
82 
 Subcellular extraction Mannosylated 
poly(anhydride) nanoparticle 
None Mice Eye drop, single dose Two-fold higher mucosal IgA titers and increased 
protective efficacy than those elicited by a live 
attenuated vaccine 
83 
 Subunit bacterial 
nucleoprotein 
PLGA microparticle None Mice i.p., two doses High level of IFN-³  secreted by splenocytes from 
immunized mice; suboptimal protection 
compared with a live attenuated vaccine 
85 
 Bacterial T-cell PLGA microparticle None Mice s.c., two doses Suboptimal protection compared with a 86 
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epitopes live-attenuated vaccine 
Salmonellosis Subcellular extraction PVM/MA nanoparticle None Mice i.p., single dose Release of IFN-³  from splenocytes; complete 
protection 
92 
 Vi polysaccharide PLA nanoparticle or 
microparticle 
Alhydrogel® Mice i.m., two doses 
(boosted with a low 
dose of soluble Vi) 
Two-fold higher memory antibody responses 
compared with a soluble vaccine; humoral 
immune responses were further enhanced by 
display of antigens on the particle surface 
93 
Shigellosis OMVs PVM/MA nanoparticle None Mice i.d., i.n., oral, or 
ocular delivery, 
single dose 




caused by E. coli 
O157:H7 
Killed whole bacteria Liposome MPLA Mice Oral, three doses Elicitation of systemic and mucosal 
antigen-specific IgG and IgA 
103 
 Stx Liposome None Mice, NHP i.p. single dose for 
mice, i.m. four doses 
for NHP 
Complete protection against a challenge by Stx 
due to robust antigen-specific serum IgG levels 
104, 
105 
        
Table 2 (Continued)        
Disease Antigen Delivery system Adjuvants Animal Model Dosing Scheme Major Results Ref. 
Poisoning by 
staphylococcal toxins 
Inactivated SEB PLGA microparticle None Monkey i.m., i.t., or oral, two 
doses with different 
routes 
Booster dose through the i.t. route achieved the 
highest antibody titers and best protection 
110 
 Inactivated SEB PLGA nanoparticle None Rabbit s.c., single dose Humoral immune responses were comparable to 
those elicited by a soluble vaccine using Alum as 
111 
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adjuvant 
 α-haemolysin Erythrocyte 
membrane-coated PLGA 
nanoparticle 
None Mice s.c., single or three 
doses 
Decreased skin toxicity, 10-fold higher 
antigen-specific IgG titers after booster doses, 
and increased protection rates compared with 
heat-inactivated toxin 
112 
Cholera Inactivated whole 
bacteria 
PLGA microparticle Amphotericin B Mice Oral, single dose Antigen-specific serum IgG and IgM levels were 
10- and 4-fold higher, compared with the soluble 
vaccine and were further enhanced by the 
adjuvant 
118 
 Inactivated whole 
bacteria 
PLGA or PLA/PEG 
microparticle 
None Mice Oral, single dose PLA/PEG particulate vaccine achieved the 
strongest humoral immune responses and the 
highest protection rate compared with PLGA 
counterparts 
119 
 Inactivated whole 
bacteria 
Eudragit® plus alginate 
microparticle 
None Rat Oral, two doses Slightly higher vibriocidal titers   than those 




None Cationic liposomes CpG Mice i.n., single dose Animals were 100% protected from an aerosol 
challenge with B. pseudomallei or B. mallei by 
enhanced IFN-³  secretion and activation of NK 
cells, but chronic diseases still occurred 
129 
 Bacterial LPS Gold nanoparticle Alhydrogel® Mice, NHP i.n. for mice, s.c. for 
NHP, three doses 




Table 2 (Continued)        
Disease Antigen Delivery system Adjuvants Animal Model Dosing Scheme Major Results Ref. 
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Intoxication with 
ricin toxin 
Inactivated toxin PLGA microparticle None Mice s.c. for a single dose; 
i.n. for two doses 
A single s.c. dose elicited systemic humoral 
immune responses, lasting for 1 year post 




 Inactivated toxin Liposome None Rat i.t., two doses Similar humoral immune responses and 
protection rates compared with soluble vaccines; 







Inactivated VEEV PLGA microparticle None Mice s.c. or i.t. for the 
prime dose, s.c., i.t., 
or oral delivery for 
one booster dose 
Higher activity of antigen-specific IgG and IgA, 
and 100% protection by the i.t. route than other 
routes for the booster dose 
145 
Abbreviations: PCL, poly(ε-caprolactone); PVM/MA, poly(methyl vinyl ester/maleic acid); PLA, poly-L-lactide; PLGA, poly(lactic-co-glycolic acid); OMVs, outer membrane vesicles; Stx, Shiga toxin; 
SEB, staphylococcal enterotoxin B; PEG, polyethylene glycol; LPS, lipopolysaccharides; NHP, non-human primate; VEEV, Venezuelan equine encephalitis virus; s.c., subcutaneous; i.p., intraperitoneal; 




DOI Article title 
10.1002/wnan.131 Topical and mucosal liposomes for vaccine delivery 
10.1002/wnan.119 Viral nanoparticles and virus-like particles: platforms for contemporary 
vaccine design 
10.1002/wnan.88 Delivery of DNA vaccines: an overview on the use of biodegradable 
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polymeric and magnetic nanoparticles 
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